Evaluation and Validation of a Crohn's Disease Inflammatory Activity Index Reflecting Pattern of Endoscopic Severity

References

• Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;7:847–69.
   Google Scholar
• Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Gastroenterology 1990;98:811–8.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budenoside with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–5.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Kjeldsen J, Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease [review]. Scand J Gastroenterol 1993;28:1–9.
   PubMed Web of Science ®Google Scholar
• Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn’s disease. Infl Bowel Dis 1995;1: 117–34.
   PubMedGoogle Scholar
• Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1984;86:249–66.
   PubMed Web of Science ®Google Scholar
• Hees van PAM, van Elteren PH, van Lier HJJ, van Tongeren JHM. An index of inflammatory activity in patients with Crohn’s disease. Gut 1980;21:279–86.
   PubMedGoogle Scholar
• Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley; 1989.
   Google Scholar
• Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. J Clin Gastroenterol 1988;10:401–5.
   PubMed Web of Science ®Google Scholar
• Miura S, Yoshioka M, Tanaka S, Serizawa H, Tashiro H, Asakura H, et al. Faecal clearance of alpha 1-antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991;6:49–52.
   PubMed Web of Science ®Google Scholar
• Andre C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn’s disease activity index. Gut 1981;22:571–4.
   PubMed Web of Science ®Google Scholar
• Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology 1986;91:1490–4.
   PubMed Web of Science ®Google Scholar
• Baba R, Yashiro K, Nagasako K, Obata H. Significance of serum sialic acid in patients with Crohn’s disease. Gastroenterol Jpn 1992;27:604–10.
   PubMedGoogle Scholar
• Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27:92–5.
   PubMed Web of Science ®Google Scholar
• Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. Gut 1994;35:231–5.
   Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Gut 1989;30:983–9.
   PubMed Web of Science ®Google Scholar
• Judmaier G, Meyersbach P, Weiss G, Wachter H, Reibnegger G. The role of neopterin in assessing disease activity in Crohn’s disease: classification and regression trees. Am J Gastroenterol 1993;88:706–11.
   Google Scholar
• Prantera C, Luzi C, Olivotto P, Levenstein S, Cerro P, Fanucci A. Relationship between clinical and laboratory parameters and length of lesion in Crohn’s disease of small bowel. Dig Dis Sci 1984;29:1093–7.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coene- grachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665–72.
   Google Scholar
• Simmich von TH, Dehne A, Laube K, Laube N, Frank KH. Sialic acid—an acute phase reactant and tumor marker. Z Med Lab Diagn 1991;32:188–92.
   Google Scholar
• Tuten MB, Wogt S, Dasse F, Leider Z. Utilization of prealbumin as a nutritional parameter. J Parenter Enteral Nutr 1985;9:709–11.
   PubMed Web of Science ®Google Scholar
• Pötzi R, Walgram M, Lochs H, Holzner H, Gangl A. Diagnostic significance of endoscopic biopsy in Crohn’s disease. Endoscopy 1989;21:60–2.
   Google Scholar
• Simonis B, Diehl S, Heine M, Heene DL, Gladisch R. Evaluation and validation of a Crohn’s disease activity index reflecting macroscopic acuteness and its relevance influencing short and long term outcome. Gut 1995;37 Suppl 2:A110–1.
   Google Scholar
• Landi B, N’Guyen Anh T, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102:1647–53.
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–8.
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996;334:1557–60.
   PubMed Web of Science ®Google Scholar